Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 109429
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109429
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109429
Interleukin-36 subfamily cytokines in liver diseases
Zhe-Kun Xiong, Department of Spleen, Stomach and Hepatobiliary, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan 528401, Guangdong Province, China
Si-Min Gu, Yi-Yuan Zheng, Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, China
Co-first authors: Zhe-Kun Xiong and Si-Min Gu.
Author contributions: Xiong ZK and Gu SM contributed equally to this work as co-first authors; Xiong ZK, Gu SM, and Zheng YY conceived this work, researched the literature, and wrote the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Supported by National Natural Science Foundation of China, No. 82104549.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Yuan Zheng, Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine, No. 274 Zhijiang Middle Road, Shanghai 200071, China. iceroser@126.com
Received: May 12, 2025
Revised: June 6, 2025
Accepted: July 31, 2025
Published online: September 27, 2025
Processing time: 138 Days and 3.6 Hours
Revised: June 6, 2025
Accepted: July 31, 2025
Published online: September 27, 2025
Processing time: 138 Days and 3.6 Hours
Core Tip
Core Tip: This letter discusses the important role of the interleukin-36 (IL-36) subfamily in the pathogenesis of liver diseases, particularly in modulating immune responses and promoting inflammation. Although considerable knowledge gaps remain regarding the precise mechanisms through which IL-36 cytokines contribute to liver damage, emerging evidence suggests that the targeting of IL-36 signaling may present novel therapeutic avenues for the management of chronic liver diseases. Further research is essential to investigate the potential of IL-36 as both a biomarker and a therapeutic target within clinical contexts.